Source : https://pubmed.ncbi.nlm.nih.gov/38363694/
Children with familial hypercholesterolemia benefit from early detection and optimal treatment of their elevated LDL-C levels.
Early detection and optimal lipid-lowering therapy in children with familial hypercholesterolemia reduce the risk of premature atherosclerotic cardiovascular disease, with novel treatments improving outcomes and cost-effectiveness.
Austria's health technology assessment (HTA) practices underutilize economic evaluations despite rising healthcare costs. This commentary proposes broadening methods beyond cost-effectiveness analysis to reflect diverse values and address high-cost technologies. Innovative approaches may enhance HTA relevance in Austria and globally.
Did you know? The World Health Organization (WHO) considers an intervention cost-effective if it costs three times a person’s income per quality-adjusted life year (QALY) gained. In the U.S., with an average income of around $40,000, this means interventions costing less than $120,000 per QALY are deemed cost-effective. Harvard economist David Cutler suggests $100,000 as a reasonable benchmark.
How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?
.png)
How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?
At the American Heart Association’s centennial conference, Dr. Amit Khera, Director of Preventive Cardiology and Professor at UT Southwestern Medical Center, and Dr. John L. Sapp, Assistant Dean of Clinical Research at Dalhousie University, presented key findings. Topics included Tirzepatide’s impact on HFpEF and obesity, the comparison of left atrial appendage closure versus anticoagulation for atrial fibrillation, intensive blood pressure control in diabetes, and insights from the VANISH2 trial on ventricular tachycardia. These findings provide healthcare professionals with evidence-based strategies to advance cardiovascular care.
Source : https://pubmed.ncbi.nlm.nih.gov/38598969/
Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment...
Homozygous familial hypercholesterolemia requires early lipid-lowering treatment. Lipoprotein apheresis effectively reduces LDL-C, but guidelines are limited. A consensus statement offers practical guidance on its use in children with this condition.